Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

84.84 -0.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.84

Massimo

84.85

Metriche Chiave

By Trading Economics

Entrata

7M

-121M

Vendite

14M

25M

EPS

-1.14

Margine di Profitto

-481.149

Dipendenti

594

EBITDA

-4.7M

-131M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+0.85% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

130M

9B

Apertura precedente

84.85

Chiusura precedente

84.84

Notizie sul Sentiment di mercato

By Acuity

70%

30%

304 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 ago 2026, 00:02 UTC

News
Correlated Moves

Delta Air Lines shares are higher in after-market trading following the court's approval of its joint venture with Grupo Aeroméxico and record Q2 revenue of $17.7 billion.

29 ago 2026, 00:02 UTC

News

Pinterest Inc shares declined in after-market trading following CFO Julia Brau Donnelly's resignation, effective October 30. Vikram Naidu will serve as interim CFO.

29 ago 2026, 00:02 UTC

News

Chevron is nearing multi-billion-dollar deals to expand operations in Venezuela, boosting shares in after-market trading amid rising global crude prices.

29 ago 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

29 ago 2026, 00:01 UTC

News

Planet Fitness shares are lower in after-market hours following a class action lawsuit alleging misleading statements about customer metrics and growth guidance.

29 ago 2026, 00:01 UTC

News

Blue Owl Capital Inc. shares rose in after-market trading following its $2.4 billion debt deal for Iren Ltd. to acquire Nvidia Blackwell Ultra GPUs.

29 ago 2026, 00:01 UTC

News

Vistra Corp reports gross revenue of $17.74 billion and net income of $944 million. Shares are higher in after-market hours, reflecting strong institutional confidence.

29 ago 2026, 00:01 UTC

News

Group 1 Automotive shares declined in after-market hours following multiple broker downgrades and price target reductions, including Barclays lowering its target to $365.

28 ago 2026, 23:56 UTC

News

nVent Electric PLC will acquire Maverick Power for $1.75 billion, with additional performance-based payments. Shares are higher during after-market hours following the announcement.

28 ago 2026, 23:46 UTC

News

Diamondback Energy shares declined after-market, despite earlier gains, amid rising market expectations for a rate hike and increased Treasury yields.

28 ago 2026, 23:46 UTC

News

Target Corp filed for a mixed securities shelf and registered 15.5 million shares under its employee incentive plan. Shares remained roughly flat in after-market hours.

28 ago 2026, 23:41 UTC

News

Blue Owl Capital gained in after-market trading after leading a $2.4 billion financing deal for Iren Ltd. to purchase Nvidia Blackwell Ultra GPUs.

28 ago 2026, 23:41 UTC

News

Group 1 Automotive Inc shares declined in after-market hours, pressured by ratings downgrades from Barclays PLC and Weiss Ratings amid rising Treasury yields.

28 ago 2026, 23:21 UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

28 ago 2026, 23:21 UTC

News

Intuit Inc. shares are trading lower in after-market hours following a class action lawsuit alleging misleading statements about its financial performance and competitive advantages.

28 ago 2026, 23:06 UTC

News

Coherus Oncology's $50 million common share offering pressures shares lower in after-market trading, marking a pullback from recent highs.

28 ago 2026, 23:06 UTC

News

BioNTech SE shares are higher in after-market trading, supported by a Strong Buy rating and a cash position of $19.28 billion for R&D efforts.

28 ago 2026, 23:06 UTC

Macro Event
News

Bitcoin is trading lower as hawkish comments from Federal Reserve Chairman Kevin Warsh raise interest rate expectations and geopolitical tensions impact investor confidence.

28 ago 2026, 23:06 UTC

Macro Event
News

Bitcoin is trading lower as hawkish comments from Federal Reserve Chairman Kevin Warsh raise interest rate hike expectations and geopolitical tensions impact market confidence.

28 ago 2026, 23:06 UTC

News

Lowe's Companies declared a quarterly cash dividend of $1.25 per share, boosting shares in after-market trading following the announcement.

28 ago 2026, 23:06 UTC

News

Visa Inc shares are higher in after-market trading following a partnership with Dunamu to develop stablecoin payments and cross-border remittance services.

28 ago 2026, 23:06 UTC

News

Michael Burry has reduced his stake in PayPal as acquisition talks with Advent International and Stripe have ended. Shares are slightly higher in after-hours trading.

28 ago 2026, 23:02 UTC

News

Halliburton Co is positioned for multi-billion-dollar deals in Venezuelan crude reserves, contributing to higher shares in after-market hours.

28 ago 2026, 23:01 UTC

News

Pinterest Inc shares declined in after-market trading following the resignation announcement of CFO Julia Brau Donnelly, effective October 30, 2026. Trading remains weak overall.

28 ago 2026, 23:01 UTC

News

Chemours Co faces an investigation by Pomerantz LLP over potential securities law violations. Shares are trading higher in after-market hours despite concerns over internal controls.

28 ago 2026, 23:01 UTC

News

Alnylam Pharmaceuticals shares rose in after-market hours, despite concerns from a failed cardiomyopathy trial. The company's market capitalization stands at $31.57 billion.

28 ago 2026, 23:01 UTC

News

Flowers Foods shares are lower in after-market trading following the filing of a mixed securities shelf, raising potential concerns about dilution and financial strategy.

28 ago 2026, 23:01 UTC

Event
News

Eli Lilly's shares rise in after-market trading following FDA approval of Mounjaro for reducing cardiovascular risks in type 2 diabetes patients.

28 ago 2026, 23:01 UTC

News

Chevron is nearing multi-billion-dollar deals to expand operations in Venezuela, targeting two heavy-oil fields. Shares are trading higher in after-market hours.

28 ago 2026, 23:01 UTC

News

McKesson Corp disclosed a cybersecurity incident affecting its information systems, with shares trading lower in after-market hours amid broader market weakness.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

0.85% in crescita

Previsioni per 12 mesi

Media 85.56 USD  0.85%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

304 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat